These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 16061750)
1. Letter regarding article by Weintraub et al, "Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure". Stecker EC; McAnulty JH Circulation; 2005 Aug; 112(5):e74. PubMed ID: 16061750 [No Abstract] [Full Text] [Related]
2. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. Szucs TD; Holm MV; Schwenkglenks M; Zhang Z; Weintraub WS; Burnier M; Erne P Cardiovasc Drugs Ther; 2006 Jun; 20(3):193-204. PubMed ID: 16775667 [TBL] [Abstract][Full Text] [Related]
4. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Chan PS; Soto G; Jones PG; Nallamothu BK; Zhang Z; Weintraub WS; Spertus JA Circulation; 2009 Jan; 119(3):398-407. PubMed ID: 19139382 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. de Pouvourville G; Solesse A; Beillat M Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835 [TBL] [Abstract][Full Text] [Related]
6. Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction? Doggrell S Expert Opin Pharmacother; 2003 Sep; 4(9):1605-7. PubMed ID: 12943490 [No Abstract] [Full Text] [Related]
7. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728 [TBL] [Abstract][Full Text] [Related]
8. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M; N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699 [TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935 [TBL] [Abstract][Full Text] [Related]
10. Eplerenone after myocardial infarction? Drug Ther Bull; 2008 Jan; 46(1):1-3. PubMed ID: 18171726 [TBL] [Abstract][Full Text] [Related]
11. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762 [TBL] [Abstract][Full Text] [Related]
12. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668 [TBL] [Abstract][Full Text] [Related]
13. Eplerenone in patients with left ventricular dysfunction. Aggarwal A N Engl J Med; 2003 Jul; 349(1):88-9; author reply 88-9. PubMed ID: 12840098 [No Abstract] [Full Text] [Related]
14. Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction. Conti CR Clin Cardiol; 2005 Jan; 28(1):1-2. PubMed ID: 15704523 [No Abstract] [Full Text] [Related]
15. Eplerenone in patients with left ventricular dysfunction. Coca SG; Buller GK N Engl J Med; 2003 Jul; 349(1):88-9; author reply 88-9. PubMed ID: 12846223 [No Abstract] [Full Text] [Related]
16. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure. Croom KF; Plosker GL Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978 [TBL] [Abstract][Full Text] [Related]
17. Eplerenone in patients with left ventricular dysfunction. Blaustein DA; Schwenk MH N Engl J Med; 2003 Jul; 349(1):88-9; author reply 88-9.. PubMed ID: 12846224 [No Abstract] [Full Text] [Related]
18. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B; Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868 [TBL] [Abstract][Full Text] [Related]
20. Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. Keating GM; Plosker GL Drugs; 2004; 64(23):2689-707. PubMed ID: 15537370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]